ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
21.540,74
0,14%
S&P 500
6.033,46
-0,07%
Dow Jones
44.624,04
0,15%
Euro vs US Dollar
1,04114
0,38%
Bitcoin
97.711,59
-0,15%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Sangamo Therapeutics Inc (SGMO) Börsenkurse

Sangamo Therapeutics Inc

Sangamo Therapeutics Inc (SGMO)

NASDAQ
1,235
-0,005
( -0,40% )
Aktualisiert: 17:16:28
Verzögert um 15 Minuten

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
1,235
Gebot
1,23
Fragen
1,24
Volumen
659.347
1,22 Tagesbereich 1,28
0,304 52-Wochen-Bereich 3,179
Marktkapitalisierung
257,679M
Handelsende
1,24
Handelsbeginn
1,24
Letzte Trade
3
@
1.2399
Letzter Handelszeitpunkt
17:16:48
Finanzvolumen
US$ 818.573
VWAP
1,2415
Durchschnittliches Volumen (3 Mio.)
7.225.019
Ausgegebene Aktien
208.646.870
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-1,00
Gewinn pro Aktie (EPS)
-1,24
Erlöse
176,23M
Nettogewinn
-257,83M

Über Sangamo Therapeutics Inc

Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemoph... Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies. Mehr anzeigen

Sektor
Biological Pds,ex Diagnstics
Branche
Biological Pds,ex Diagnstics
Website
www.sangamo.com
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Sangamo Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker SGMO. The last closing price for Sangamo Therapeutics was US$1,24. Over the last year, Sangamo Therapeutics shares have traded in a share price range of US$ 0,304 to US$ 3,179.

Sangamo Therapeutics currently has 208.646.870 shares in issue. The market capitalisation of Sangamo Therapeutics is US$258,72 million. Sangamo Therapeutics has a price to earnings ratio (PE ratio) of -1.00.

SGMO Neueste Nachrichten

Weitere Nachrichten

Form 4 - Statement of changes in beneficial ownership of securities

24 Januar 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

24 Januar 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

24 Januar 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

24 Januar 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

24 Januar 2025
Edgar (US Regulatory)

Form 8-K - Current report

30 Dezember 2024
Edgar (US Regulatory)

Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec

- Based on positive results from Phase 3 AFFINE trial, which met primary and secondary endpoints, Sangamo plans to explore all options to commercialize the asset, including seeking a potential...

30 Dezember 2024
Business Wire

Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases PR Newswire TOKYO and RICHMOND, Calif., Dec. 19, 2024  - Agreement...

19 Dezember 2024
PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities

26 November 2024
Edgar (US Regulatory)
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.11510.26785714291.121.28521.137881331.20380726CS
4-0.105-7.835820895521.341.3684144327441.14166103CS
12-1.015-45.11111111112.252.840.9172250191.787959CS
260.48564.66666666670.753.1790.782174851.50567462CS
520.725142.1568627450.513.1790.30474279201.14769399CS
156-4.335-77.82764811495.576.420.291136304091.60875265CS
260-6.215-83.42281879197.4519.430.291128293873.67165761CS

SGMO - Frequently Asked Questions (FAQ)

What is the current Sangamo Therapeutics share price?
The current share price of Sangamo Therapeutics is US$ 1,235
How many Sangamo Therapeutics shares are in issue?
Sangamo Therapeutics has 208.646.870 shares in issue
What is the market cap of Sangamo Therapeutics?
The market capitalisation of Sangamo Therapeutics is USD 258,72M
What is the 1 year trading range for Sangamo Therapeutics share price?
Sangamo Therapeutics has traded in the range of US$ 0,304 to US$ 3,179 during the past year
What is the PE ratio of Sangamo Therapeutics?
The price to earnings ratio of Sangamo Therapeutics is -1
What is the cash to sales ratio of Sangamo Therapeutics?
The cash to sales ratio of Sangamo Therapeutics is 1,46
What is the reporting currency for Sangamo Therapeutics?
Sangamo Therapeutics reports financial results in USD
What is the latest annual turnover for Sangamo Therapeutics?
The latest annual turnover of Sangamo Therapeutics is USD 176,23M
What is the latest annual profit for Sangamo Therapeutics?
The latest annual profit of Sangamo Therapeutics is USD -257,83M
What is the registered address of Sangamo Therapeutics?
The registered address for Sangamo Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Sangamo Therapeutics website address?
The website address for Sangamo Therapeutics is www.sangamo.com
Which industry sector does Sangamo Therapeutics operate in?
Sangamo Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
RNAZTransCode Therapeutics Inc
US$ 10,6035
(72,13%)
12,16M
ASSTAsset Entities Inc
US$ 0,8919
(62,37%)
132,2M
ACBAurora Cannabis Inc
US$ 5,4149
(47,14%)
53,59M
KTTAPasithea Therapeutics Corporation
US$ 3,03
(45,67%)
53,8M
PWMPrestige Wealth Inc
US$ 2,1505
(33,57%)
965,63k
VLCNVolcon Inc
US$ 1,8559
(-42,00%)
2,75M
LYTLytus Technologies Holdings PTV Ltd
US$ 0,4094
(-32,17%)
790,82k
CSAICloudastructure Inc
US$ 9,09
(-29,97%)
100,29k
COEPCoeptis Therapeutics Holdings Inc
US$ 8,8227
(-26,96%)
72,84k
SDASunCar Technology Group Inc
US$ 7,72
(-25,05%)
415,86k
CYNCYNGN Inc
US$ 0,0888
(25,07%)
355,18M
RIMEAlgorhythm Holdings Inc
US$ 0,02005
(-17,83%)
151,08M
ASSTAsset Entities Inc
US$ 0,8919
(62,37%)
132,2M
NVDANVIDIA Corporation
US$ 123,445
(4,04%)
113,65M
TLRYTilray Brands Inc
US$ 1,155
(15,50%)
60,01M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
SGMO
Sangamo Therapeutics
EU
XS2229470146
Koninklijke KPN 0.875% u...
LSE
SMS
Smart Metering Systems
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten

Werbung entfernen

Melden Sie sich für ein werbefreies Erlebnis an

Keine Werbung

Versuchen Sie es jetzt

Anzeigen behalten